Home / Health / Two-Thirds of Myeloma Patients Reach Remission with New Therapy
Two-Thirds of Myeloma Patients Reach Remission with New Therapy
3 Jun
Summary
- New immunotherapy shows significant remission rates for relapsed multiple myeloma.
- 70% of patients treated with teclistamab saw no cancer progression for 18 months.
- The treatment targets myeloma cells by linking them to immune T cells.
A new clinical trial reveals that a recently approved cancer immunotherapy, teclistamab, can induce complete remission in nearly two-thirds of patients with relapsed multiple myeloma. This development offers a significant chemotherapy-free option for individuals whose cancer has returned.
The study, published on May 29, 2026, in The New England Journal of Medicine, involved nearly 600 patients across 24 countries. Participants had multiple myeloma that had relapsed after one to three prior treatments.
Teclistamab demonstrated impressive efficacy, with approximately 70% of patients achieving 18 months without cancer progression, compared to about 27% on standard treatment. Furthermore, about 66% achieved complete remission, meaning no detectable cancer, versus 17% in the standard treatment group.
This immunotherapy functions by linking immune hunter/killer T cells to myeloma cells, enhancing their ability to target the cancer. Beyond remission, teclistamab also improved overall survival, with 79% surviving at 18 months, compared to nearly 69% in the control group.
While generally safe, teclistamab carries a higher risk of infection. Patients require close monitoring and preventive medications. Researchers are now investigating its potential as a first-line treatment, aiming for curative strategies that minimize patient burden and preserve quality of life.
